Cellular Therapies tissue manipulation and clinical solutions Cell Therapies
 
Cell Therapies delivers flexible solutions across the full spectrum of clinical trials involving cell and tissue manipulation
 
 
the Centre for Blood Cell Therapies Clean Rooms

Clean Room facilities include 23m2 high speed cell sorting laboratory suitable for research activities and a second high speed cell sorting clean room, 20m2, set-up for clinical cell sorting for patient use.

Loading an incubator in a Clean Room

The research sorting room is equipped with FACStar Plus FACS-DIVA and FACS-CALIBUR. R5 is utilized for clinical sorting and processing of patients, and is equipped with FACSVantage SE
Special laboratory features |

NEWS + DEVELOPMENTS
  1. Bid To Beat Toxic Anti Cancer Drugs
    Article in the Melbourne AGE, February 22 2011
    Professor Miles Prince of the Peter MacCallum Cancer Centre and his colleagues are testing epigenetic drugs that switch off the controlling mechanisms of genes inside cancerous cells rather than killing them with toxic agents.

    --------------------------------------------------------------------------------

  2. Update on Peter Mac and CT Research Activities
    October 2010
    Effective collaboration between laboratory and clinical researchers is vital for improving the outcomes of patients with cancer

    --------------------------------------------------------------------------------

  3. Clinical and Commercial Solutions
    The key to the Celll Therapies Pty Ltd’s success is its attention to the needs of researchers and clinicians, in combination with the commercial imperatives of bringing a new therapy to market

    --------------------------------------------------------------------------------

  4. Mesoblast Applies For TGA Licence
    Melbourne, Australia, July 2009
    Earlier Revenues Anticipated Through Distribution To Australian Hospitals And Clinicians

    --------------------------------------------------------------------------------

  5. Cell Therapies P/L Secures NCRIS Subsidies for its Clients
    Dec/2008
    CT also received a $50,000 subsidy for the maintenance of its own TGA license.

    --------------------------------------------------------------------------------

  6. Research Grant
    The $10.8 million Grant has been awarded to better understand the molecular basis of cell death and the complex cellular interactions involved in cell-mediated cancer immunity.

    --------------------------------------------------------------------------------

  7. New Lab Helps Translate Research
    The Haematology Immunology Translational Research Laboratory (HITRL) is a bridge between the Centre’s world-class cancer immunologists and clinical researchers within its Haematology Department, according to Dr David Ritchie, Deputy Director, Centre for Blood Cell Therapies (CBCT) at Peter MacCallum

    --------------------------------------------------------------------------------

 
 
In association with Peter MacCallum Cancer Research - Genetics, Genomics and Biotechnology BioMelbourne Network - Progressing BioIndustry
Cell Therapies Pty Ltd ABN 100 285 916